5 and 5 mg/kg BW) of 17-DMAG in vivo.

Because LPS-induced liver injury is largely mediated by proinflammatory cytokines, we determined whether 17-DMAG would have any effect on proinflammatory cytokine production in the liver. First, we analyzed messenger RNA (mRNA) levels of proinflammatory cytokines by real-time PCR in whole livers after treatment with 17-DMAG in vivo. Proinflammatory cytokine TNFα mRNA (Fig. 2A) was significantly reduced at 2.5 and 5 mg/kg of 17-DMAG treatment, compared to LPS alone, whereas IL-6 mRNA (Fig. 2B) was decreased at the higher dose (5 mg/kg) of 17-DMAG, compared to LPS alone, in the liver. Second, we measured serum cytokine levels Selleckchem AUY-922 by enzyme-linked immunosorbent assay (ELISA) and observed that TNFα (Fig. 2C) was significantly reduced at both doses of 17-DMAG, whereas IL-6 (Fig. 2D) showed significant reduction only at the 5-mg/kg 17-DMAG dose, compared to LPS alone. These results suggest that hsp90 inhibition by 17-DMAG prevented the LPS-induced proinflammatory cytokines, TNFα and IL-6, at both mRNA and protein levels in the liver. Hsp90 sequesters HSF1 in an inactive state in cytoplasm,29 and inhibition of hsp90 dissociates this

complex and releases HSF1, which translocates to the nucleus.30 To confirm the inhibition of hsp90 activity in the liver, we analyzed the DNA-binding activity of HSF1 by EMSA and expression of the target gene, hsp70. Hsp90 KU-57788 price inhibition by 17-DMAG significantly up-regulated

HSF1 binding to DNA in a dose-dependent manner (Fig. 3A) in the liver. Complementary to HSF1 activation, hsp90 inhibition resulted in subsequent induction of hsp70 mRNA (Fig. 3B) and protein levels (Fig. 3C) in the liver. In accord with the reported action of 17-DMAG on hsp90 chaperone function,31 no effect was observed on protein levels of hsp90 in the liver (Fig. 3D). Our results suggest that 17-DMAG up-regulates HSF1 DNA-binding activity and induces target gene hsp70, without affecting hsp90 levels, confirming the inhibition of hsp90 function after 17-DMAG treatment in the liver. Hsp90 chaperones the LPS receptors, cluster of differentiation 14 (CD14) and TLR4, resulting in the activation of downstream MCE公司 signaling and proinflammatory cytokine production.14 We assessed CD14 and TLR4 mRNA levels, as a measure of total cellular expression, in response to hsp90 inhibition. Liver CD14 mRNA was significantly down-regulated in response to hsp90 inhibition by 17-DMAG, compared to LPS alone (Fig. 4A), whereas TLR4 mRNA was unaffected (Fig. 4A). Subsequently, to determine the effect of 17-DMAG on downstream activation, we analyzed NFκB, a pivotal transcription factor in CD14/TLR4 signaling. Our results show that 17-DMAG treatment significantly decreased LPS-induced NFκB DNA-binding activity in a dose-dependent manner (Fig. 4B).